The answers to the biggest questions in the future of drug discovery & development are there - if only we know where to look, and how to apply what we learn. In this route, Excelra exists to find and reveal the precious value that is encoded in data; using our unique combination of proven expertise in data, technology, and domain, we empower life science innovation, revealing value at every stage. The result? Faster, smarter, and altogether more innovative drug development, for better patient outcomes.

GVK BIO, is now rebranded as Aragen Life Sciences Ltd. To keep updated about the latest development at Aragen, follow us at https://www.linkedin.com/company/68794876/admin/

Aragen is a trusted R&D and manufacturing partner to the global life sciences industry. From concept to commercial, we transform your ideas into solutions for better health. Whether large pharma or biotech, an agrochemical or animal health company, we provide you global resources and proven capabilities at every stage of the biopharma lifecycle, in small and large molecules. Our ability to offer end-to-end solutions or support standalone programs is underpinned by an innovation mindset, enabling technologies, and a partnership approach to every engagement. At Aragen, we recognize your work is vital, urgent and impacts lives. Our purpose, ‘In every molecule is the possibility for better health’ motivates us to drive the success of your programs, so that we can together transform hope into health for millions of people around the world.

India's Council of Scientific and Industrial Research (CSIR) has a specialized service Unit for Research and Development of Information Products (URDIP) at Pune which is involved in the pre-research and pre- development phase of the research projects by providing intellectual property and techno-commercial information services. CSIR-URDIP provides value added information services to wide array of clients including start-up companies, SMEs, Research Institutes within and outside CSIR, Academic Institutes, Large Indian Corporate and Multinational Corporations. Our primary clients include R&D, legal, new business development and mutifunctional corporate teams. CSIR-URDIP provides value added information services in the following areas: Patinformatics Toxinformatics Phytoinformatics Cheminformatics

Through two business units, SS&C DST Health provides pharmacy, healthcare administration, and health outcomes optimization solutions to health plans in the commercial and government sectors, PBMs, integrated health systems, and providers. We help plans optimize clinical, operational and financial outcomes by integrating data, analytics, and insights with leading technology, business services and strategic advisory. DST Pharmacy Solutions, Inc. Pharmacy Solutions helps plans optimize the value in pharmacy benefits and improve clinical outcomes for their members, improve financial performance, reduce administrative burdens, and manage compliance requirements. Our flexible administrative platform supports and operationalizes all plan types, which helps to reduce the resources needed to manage multiple systems, data silos and vendors. Our deep experience in data management and advanced analytics combine with clinical expertise to create convergent solutions that help transform and support coordinated care models and improve physician, pharmacy and member alignment. DST Health Solutions, LLC Health Solutions delivers contemporary healthcare technology and service solutions that enable its clients to thrive in a complex, rapidly evolving healthcare market. Supporting all plan types and healthcare providers, DST Health Solutions’ services include enterprise payer platforms, population health management analytics, care management, and business process outsourcing solutions - each designed to assist a company with managing the processes, information, and products that directly impact quality outcomes. DST Systems, Inc. Was acquired by SS&C Technologies on April 16, 2018. SS&C provides the global financial services industry with a broad range of highly specialized software, software enabled-services and software as a service (SaaS) solutions for operational excellence. Additional information about SS&C is available at www.ssctech.com

Ranbaxy Laboratories Limited, India's largest pharmaceutical company, is an integrated, research based, international pharmaceutical company, producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. Ranked 8th amongst the global generic pharmaceutical companies, Ranbaxy today has a presence in 23 of the top 25 pharmaceutical markets of the world. The Company has a global footprint in 49 countries, world-class manufacturing facilities in 11 countries and serves customers in over 125 countries. In June 2008, Ranbaxy entered into an alliance with one of the largest Japanese innovator companies, Daiichi Sankyo Company Ltd., to create an innovator and generic pharmaceutical powerhouse. The combined entity now ranks among the top 15 pharmaceutical companies, globally. The transformational deal will place Ranbaxy in a higher growth trajectory and it will emerge stronger in terms of its global reach and in its capabilities in drug development and manufacturing. Vision & Aspirations Ranbaxy is driven by its vision to achieve significant business in proprietary prescription products by 2012 with a strong presence in developed markets. The Company aspires to be amongst the Top 5 global generic players and aims at achieving global sales of US $5 Bn by 2012. Financials Ranbaxy was incorporated in 1961 and went public in 1973. For the year 2008, the Company recorded Global Sales of US $ 1,682 Mn, reflecting a growth of 4%. The Company has a balanced mix of revenues from emerging and developed markets that contribute 54% and 39% respectively. In 2008, North America, the Company's largest market contributed sales of US $ 449 Mn, followed by Europe garnering US $ 330 Mn. Business in Asia has been going strong with India clocking sales of around US $ 300 Mn with market leadership in several business segments, backed by strong brand-building skills.